Healthcare - Biotechnology - NASDAQ - CH
$ 3.13
-6.29 %
$ 7.74 M
Market Cap
-0.46
P/E
INCOME STATEMENT
0
REVENUE
-11.8 M
OPERATING INCOME
-12.2 M
NET INCOME
EFFICIENCY
Earnings Waterfall
NLS Pharmaceutics AG
| Revenue | 0 |
| Cost Of Revenue | 11.4 K |
| Gross Profit | -11.4 K |
| Operating Expenses | 11.8 M |
| Operating Income | -11.8 M |
| Other Expenses | 365 K |
| Net Income | -12.2 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||
| Cost Of Revenue | 11.4 K | 11.4 K | 10 K | 0 | 0 | 0 | 0 |
| Gross Profit | 11.4 K | 11.4 K | 10 K | 0 | 0 | 0 | 0 |
| OPERATING INCOME | |||||||
| Operating Expenses | 11.8 | 15.5 | 11.9 | 2.3 | 4.2 | 3.4 | 5.8 |
| Selling, General and Administrative Expenses | 5.9 | 6.5 | 5.9 | 2.2 | 2.5 | 2.0 | 1.4 |
| Research and Development Expenses | 5.9 | 9.0 | 5.9 | 99.6 K | 1.7 | 1.4 | 4.3 |
| Operating Income | (11.8) | (15.5) | (11.9) | (2.3) | (4.2) | (3.4) | (5.8) |
| PRE-TAX INCOME | |||||||
| Interest Income Expense | 0.1 | 0.1 | 68.1 K | 0.2 | 0.8 | 1.1 | 0.9 |
| Total Other Income | (0.4) | (1.0) | 85.5 K | (0.6) | (1.3) | (1.7) | (0.9) |
| Pre-Tax Income | (12.2) | (16.5) | (11.9) | (2.9) | (5.4) | (5.1) | (6.7) |
| NET INCOME | |||||||
| Tax Provision | 0 | 2 | (0.2) | 2.3 K | 4.2 K | 1.7 | 5.77 K |
| Net Income | (12.2) | (16.5) | (11.9) | (2.9) | (5.4) | (5.1) | (6.7) |
| EPS | 0.32 | 0.84 | 0.81 | 0.59 | 0.49 | 0.44 | 0.57 |